阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

AZN 阿斯利康

盘前交易 06-16 07:13:20 EDT

177.27

-1.48

-0.83%

盘前178.35

+1.08+0.61%

07:06 EDT

最高179.22	最低176.55	成交量132.91万
今开179.16	昨收178.75	日振幅1.49%
总市值2,749亿	流通市值2,737亿	总股本15.51亿
成交额2.36亿	换手率0.09%	流通股本15.44亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

{"stockData":{"symbol":"AZN","market":"US","secType":"STK","nameCN":"阿斯利康","latestPrice":177.27,"timestamp":1781553600000,"preClose":178.75,"halted":0,"volume":1329084,"hourTrading":{"tag":"盘前","latestPrice":178.35,"preClose":177.27,"latestTime":"07:06 EDT","volume":3306,"amount":588751.19196,"timestamp":1781607977006,"change":1.08,"changeRate":0.006092,"amplitude":0.00574},"delay":0,"changeRate":-0.008279720279720222,"floatShares":1544000000,"shares":1551000000,"eps":6.639935,"marketStatus":"盘前交易","change":-1.48,"latestTime":"06-16 07:13:20 EDT","open":179.16,"high":179.22,"low":176.55,"amount":235797364.48896,"amplitude":0.014937,"askPrice":178.24,"askSize":50,"bidPrice":178.16,"bidSize":291,"shortable":3,"etf":0,"ttmEps":6.639935,"tradingStatus":1,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1781616600000},"marketStatusCode":1,"adr":1,"adrRate":0.5,"listingDate":737179200000,"exchange":"NYSE","adjPreClose":177.27,"dividendRate":0.0179,"preHourTrading":{"tag":"盘前","latestPrice":178.35,"preClose":177.27,"latestTime":"07:06 EDT","volume":3306,"amount":588751.19196,"timestamp":1781607977006,"change":1.08,"changeRate":0.006092,"amplitude":0.00574},"postHourTrading":{"tag":"盘后","latestPrice":177.6,"preClose":177.27,"latestTime":"19:54 EDT","volume":18079,"amount":3204824.5901,"timestamp":1781567656095,"change":0.33,"changeRate":0.001862,"amplitude":0.003345},"volumeRatio":0.6466088845416983,"impliedVol":0.2676,"impliedVolPercentile":0.404},"requestUrl":"/m/hq/s/AZN","defaultTab":"news","newsList":[{"id":"2642189402","title":"重返肿瘤核心战场 葛兰素史克(GSK.US)能否借Nuvalent缩小与阿斯利康差距？","url":"https://stock-news.laohu8.com/highlight/detail?id=2642189402","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642189402?lang=zh_cn&edition=full","pubTime":"2026-06-11 15:56","pubTimestamp":1781164594,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，葛兰素史克以创纪录的106亿美元收购美国生物技术公司Nuvalent，此举将加快这家英国制药巨头旗下抗癌药物业务的重建步伐，以应对来自更大竞争对手阿斯利康和罗氏的竞争压力。米尔斯在周二宣布收购Nuvalent后对记者表示。葛兰素史克并不打算在全部肿瘤领域与默沙东、阿斯利康或罗氏正面竞争，但将其视为潜在的增长领域。收购Nuvalent将为葛兰素史克产品组合增添两款晚期药物。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1453096.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["LU0289739699.SGD","LU0109394709.USD","LU2236285917.USD","BK4139","IE00B3T34201.USD","LU2237443382.USD","LU0889565916.HKD","AZNH","BK4532","LU2237443465.HKD","BK4585","BK4568","LU2417539215.USD","BK4588","BK4007","LU2237443978.SGD","LU2456880835.USD","NUVL","AZN","GSK.UK","LU2237443622.USD","LU2462157665.USD","BK4539","LU0320765992.SGD","LU2237443895.HKD","GSK","LU0058720904.USD","LU1829250122.USD","LU2237443549.SGD","GSKH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1159679098","title":"异动解读｜阿斯利康盘中下跌3.03%，口服减肥药数据竞争力逊于同业叠加管线压力","url":"https://stock-news.laohu8.com/highlight/detail?id=1159679098","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1159679098?lang=zh_cn&edition=full","pubTime":"2026-06-11 01:34","pubTimestamp":1781112877,"startTime":"0","endTime":"0","summary":"6月10日，阿斯利康盘中下跌3.03%，报177.88美元/股，成交额1.96亿美元。消息面上，公司近日公布口服减肥药elecoglipron II期数据，最高剂量组36周减重11.8%，低于诺和诺德口服Wegovy约14%的减重幅度及礼来Foundayo约12%的水平，市场对其肥胖赛道竞争力存疑。此外，核心管线camizestrant此前遭FDA延长审评周期，管线不确定性持续累积。制药板块同业中，诺和诺德涨2.69%、强生涨0.81%，阿斯利康跌幅明显超出行业整体水平，反映市场对其管线兑现能力的担忧。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642452868","title":"阿斯利康加入减肥药赛道：口服药减重11.8%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642452868","media":"华尔街见闻","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2642452868?lang=zh_cn&edition=full","pubTime":"2026-06-09 14:19","pubTimestamp":1780985960,"startTime":"0","endTime":"0","summary":"阿斯利康的口服减肥药elecoglipron二期数据亮眼，36周内减重11.8%。虽效果略逊于礼来，但5%的副作用退出率远低于礼来的17%，且无需空腹。目前该药已进三期，正推进与心肾药联合开发以形成差异化竞争。","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"6e7a4338b1034ad785d5025385d8625c","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wallstreetcn.com/articles/3774191","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0058720904.USD","LU2237443622.USD","LU2237443382.USD","LU2237443465.HKD","LU2237443549.SGD","LU2417539215.USD","AZNH","LU2237443978.SGD","LU1829250122.USD","BK4007","LU0889565916.HKD","LU2236285917.USD","BK4568","BK4585","BK4588","LU0320765992.SGD","LU0109394709.USD","AZN","LU2456880835.USD","LU0289739699.SGD","LU2237443895.HKD","IE00B3T34201.USD","LU2462157665.USD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"1163381786","title":"阿斯利康GLP-1口服药在糖尿病与肥胖症试验中通过早期考验","url":"https://stock-news.laohu8.com/highlight/detail?id=1163381786","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1163381786?lang=zh_cn&edition=full","pubTime":"2026-06-09 06:27","pubTimestamp":1780957629,"startTime":"0","endTime":"0","summary":"根据周一在美国糖尿病协会年度会议上公布的二期试验结果，阿斯利康的实验性GLP-1口服药在为期36周的治疗中，使肥胖患者的体重平均降低了近12%。同时，该药物将糖尿病患者的糖化血红蛋白水平——一项衡量血糖的关键指标——平均降低了1.9个百分点。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU1829250122.USD","LU2237443382.USD","BK4144","LU2237443895.HKD","LU2237443465.HKD","LU2456880835.USD","AZN","BK4007","LU2237443978.SGD","GLP","AZNH","BK4568","LU2462157665.USD","BK4590","BK4588","LU0109394709.USD","LU2237443622.USD","LU2236285917.USD","LU2417539215.USD","LU2237443549.SGD","LU0058720904.USD","LU0320765992.SGD","LU0289739699.SGD","LU0889565916.HKD","IE00B3T34201.USD","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1189391449","title":"异动解读｜阿斯利康盘中上涨3.06%，肝癌免疫联合疗法III期数据积极叠加制药板块整体走强","url":"https://stock-news.laohu8.com/highlight/detail?id=1189391449","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1189391449?lang=zh_cn&edition=full","pubTime":"2026-06-04 22:37","pubTimestamp":1780583874,"startTime":"0","endTime":"0","summary":"6月4日，阿斯利康盘中上涨3.06%，报181.765美元/股，成交额8129.96万美元。该积极数据有效对冲了此前anselamimab治疗轻链淀粉样变性III期临床未达主要终点的利空情绪。此外，制药板块当日整体走强，礼来涨4.63%、诺和诺德涨4.62%、默沙东涨3.66%、强生涨1.96%、辉瑞涨1.62%，板块联动效应助推公司股价反弹。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1112961216","title":"异动解读｜阿斯利康盘前下跌3.18%，III期临床未达主要终点影响持续发酵","url":"https://stock-news.laohu8.com/highlight/detail?id=1112961216","media":"行情直击","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1112961216?lang=zh_cn&edition=full","pubTime":"2026-06-03 18:35","pubTimestamp":1780482907,"startTime":"0","endTime":"0","summary":"6月3日，阿斯利康盘前下跌3.18%，报171.94美元/股，成交额57.72万美元。消息面上，公司旗下Alexion罕见病部门此前披露，评估anselamimab治疗轻链淀粉样变性的CARES III期临床项目在总体患者人群中未达到主要终点。尽管预设Kappa亚组显示全因死亡率改善62%、心血管住院率降低71%，但整体数据未能达标，构成管线层面利空。当前制药板块同业表现相对平稳，礼来涨0.1%、强生涨0.11%、默沙东涨0.2%，阿斯利康跌幅明显超出行业整体水平，反映市场对其管线风险的持续定价。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1128310629","title":"异动解读｜阿斯利康盘中下跌3.03%，III期临床未达主要终点叠加制药板块整体承压","url":"https://stock-news.laohu8.com/highlight/detail?id=1128310629","media":"行情直击","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/1128310629?lang=zh_cn&edition=full","pubTime":"2026-06-01 22:53","pubTimestamp":1780325597,"startTime":"0","endTime":"0","summary":"6月1日，阿斯利康盘中下跌3.03%，报180.16美元/股，成交额8859.88万美元。消息面上，公司旗下Alexion罕见病部门近日披露，评估anselamimab治疗轻链淀粉样变性的CARES III期临床项目在总体患者人群中未达到主要终点。尽管预设Kappa亚组显示全因死亡率改善62%、心血管住院率降低71%，但整体数据未能达标，构成管线层面利空。此外，制药行业当日普遍走弱，礼来跌2.16%、强生跌1.54%、辉瑞跌2.5%、默沙东跌2.97%、施贵宝跌3.67%，板块联动效应加剧公司股价下行压力。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["AZN"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639256620","title":"阿斯利康(AZN.US)本瑞利珠单抗新适应症获批上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2639256620","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639256620?lang=zh_cn&edition=full","pubTime":"2026-05-29 21:10","pubTimestamp":1780060236,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，5月29日，NMPA官网显示，阿斯利康本瑞利珠单抗一项新适应症获批上市，用于治疗成人和 12 岁及以上青少年患者无明确非血液学继发性病因的嗜酸性粒细胞增多综合征。在国际多中心 III 期 NATRON 临床试验中，阿斯利康评估了本瑞利珠单抗治疗 HES 患者的有效性和安全性，试验的主要研究终点为患者至首次恶化或复发的时间。研究结果显示，与安慰剂相比，本瑞利珠单抗显著延缓了患者首次 HES 发作的时间，发作风险降低 65%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1448031.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IPOS","LU0320765992.SGD","LU2236285917.USD","LU0889565916.HKD","LU0289739699.SGD","LU2462157665.USD","LU0058720904.USD","BK4568","LU1829250122.USD","IE00B3T34201.USD","BK4007","BK4588","BK4585","LU2237443382.USD","LU2456880835.USD","LU2237443978.SGD","LU2237443895.HKD","AZNH","LU2237443622.USD","LU2417539215.USD","LU0109394709.USD","AZN","LU2237443465.HKD","LU2237443549.SGD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639627307","title":"石药集团(01093)：收到阿斯利康就创新长效多肽药物开发的战略合作与授权协议项下的12亿美元首付款","url":"https://stock-news.laohu8.com/highlight/detail?id=2639627307","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2639627307?lang=zh_cn&edition=full","pubTime":"2026-05-29 20:19","pubTimestamp":1780057161,"startTime":"0","endTime":"0","summary":"智通财经APP讯，石药集团(01093)发布公告，内容有关集团与阿斯利康签订战略研发合作与授权协议(该协议)。集团与阿斯利康签订该协议，以利用集团所拥有的长效递送技术平台及多肽药物AI发现平台，开发创新长效多肽药物，并将根据该协议条款(其中包括)收取12亿美元的首付款。董事会欣然宣布，集团已于2026年5月29日(交易时间后)收到上述阿斯利康支付的首付款12亿美元。该首付款的收取将为集团的财务状况带来正面贡献。目前，双方的合作进展顺利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LU2456880835.USD","AZNH","LU1328277881.USD","LU2237443622.USD","LU0326950275.SGD","BK4007","LU1226287875.USD","LU1152091754.HKD","LU0072913022.USD","LU2237443465.HKD","LU0140636845.USD","LU1226287792.SGD","LU1226288253.USD","LU0501845795.SGD","BK4588","LU2462157665.USD","LU1960683339.HKD","LU2237443382.USD","LU2237443978.SGD","LU2237443895.HKD","BK1521","LU1829250122.USD","BK4585","IE0008369823.USD","BK1191","LU1813983027.USD","LU1152091168.USD","IE00BZ08YS42.EUR","IE00B031HY20.USD","LU0289739699.SGD","AZN","BK1515","LU2236285917.USD","LU0058720904.USD","LU2417539215.USD","LU1226288170.HKD","LU2039709279.SGD","01093","LU0067412154.USD","LU0109394709.USD","BK4568","LU0314109678.HKD","IE0008368742.USD","LU0880133367.SGD","LU1226287529.USD","LU0889565916.HKD","IE00BZ08YR35.GBP","LU1807302812.USD","LU0315179316.USD","LU1008478684.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637334314","title":"阿斯利康将在ASCO 2026公布多项III期数据，涵盖肝癌、乳腺癌、膀胱癌及罕见病疗法","url":"https://stock-news.laohu8.com/highlight/detail?id=2637334314","media":"环球市场播报","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637334314?lang=zh_cn&edition=full","pubTime":"2026-05-22 23:33","pubTimestamp":1779463980,"startTime":"0","endTime":"0","summary":"阿斯利康于5月22日宣布，将在5月29日至6月2日举行的2026年美国临床肿瘤学会年会上，公布超过85篇摘要，涵盖10款已获批药物和13款潜在新药，其中包括25项口头报告。　　在肝癌方面，将公布EMERALD-3 III期试验结果。　　在膀胱癌方面，将公布POTOMAC III期试验的5年总生存期分析，该试验评估了Imfinzi联合卡介苗治疗高危非肌层浸润性膀胱癌的疗效。　　在罕见病方面，将展示anselamimab的III期临床项目数据。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyuwee5028220.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443895.HKD","LU2462157665.USD","LU2237443549.SGD","LU1829250122.USD","IE00B3T34201.USD","BK4568","LU0289739699.SGD","LU2237443382.USD","LU2456880835.USD","III","LU0109394709.USD","LU0320765992.SGD","LU2236285917.USD","BK4007","BK4585","LU2417539215.USD","AZNH","AZN","LU0058720904.USD","BK4134","LU2237443622.USD","LU0889565916.HKD","BK4588","LU2237443978.SGD","LU2237443465.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637889316","title":"欧洲药品管理局对阿斯利康乳腺癌新药给予积极指导意见","url":"https://stock-news.laohu8.com/highlight/detail?id=2637889316","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2637889316?lang=zh_cn&edition=full","pubTime":"2026-05-22 18:57","pubTimestamp":1779447420,"startTime":"0","endTime":"0","summary":"欧洲药品管理局下属委员会22日发布评估结论，对阿斯利康公司研发的实验性乳腺癌药物camizestrant正式出具积极意见。　　该决定与美国监管部门此前的初步立场形成对比。数周前，美国食品药品监督管理局顾问委员会曾投票否决该疗法的相关申请。　　加速新药获批是阿斯利康扩大全球市场份额的核心战略。据阿斯利康预测，camizestrant仍有望于今年内获得美国监管机构批准，其年销售额峰值预计将突破50亿美元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-22/doc-inhyumqk5199163.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0320765992.SGD","LU1829250122.USD","LU2237443978.SGD","LU2237443549.SGD","LU0109394709.USD","LU2237443465.HKD","BK4568","IE00B3T34201.USD","LU2237443382.USD","AZN","LU2462157665.USD","LU2236285917.USD","BK4007","LU0889565916.HKD","LU0058720904.USD","LU0289739699.SGD","AZNH","BK4585","LU2237443895.HKD","LU2456880835.USD","BK4588","LU2237443622.USD","LU2417539215.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636700080","title":"广药接手达安基因；阿斯利康高血压创新药获美国FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2636700080","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636700080?lang=zh_cn&edition=full","pubTime":"2026-05-19 08:01","pubTimestamp":1779148914,"startTime":"0","endTime":"0","summary":"政策动向2026年医保目录调整新增预申报允许商保创新药申报医保目录国家医保局介绍2026年国家医保药品目录及商业健康保险创新药品目录调整工作安排，包括首次允许纳入2025年商保创新药目录的药品申报国家医保目录，新增“预申报”环节等。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202605193741160824.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202605193741160824.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU2462157665.USD","BK0239","159992","LU2237443465.HKD","LU0320765992.SGD","LU0289739699.SGD","LU2237443622.USD","AZN","LU2237443382.USD","LU2456880835.USD","LU2237443549.SGD","AZNH","BK0122","BK4007","LU2237443978.SGD","002030","BK0028","BK4588","IE00B3T34201.USD","LU2237443895.HKD","LU0889565916.HKD","BK1574","BK0188","LU1829250122.USD","LU2236285917.USD","06978","LU2417539215.USD","BK0046","BK4585","LU0058720904.USD","BK1161","LABU","BK4568","BK0042","BK0168","BK0159","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636023010","title":"阿斯利康(AZN)旗下创新降压药Baxfendy获批 加码高血压治疗领域","url":"https://stock-news.laohu8.com/highlight/detail?id=2636023010","media":"金吾财讯","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2636023010?lang=zh_cn&edition=full","pubTime":"2026-05-18 16:21","pubTimestamp":1779092477,"startTime":"0","endTime":"0","summary":"从安全性来看，Baxfendy 总体耐受性良好，临床试验期间未发现任何意外安全问题，用药安全性得到充分验证。","market":"us","thumbnail":"https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/NjEzNTY0MzU5MDE2.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300527","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0289739699.SGD","LU0889565916.HKD","LU2237443895.HKD","LU2417539215.USD","AZN","BK4588","LU0320765992.SGD","LU2237443382.USD","LU1829250122.USD","AZNH","BK4585","LU2236285917.USD","LU2237443978.SGD","BK4007","LU2237443465.HKD","IE00B3T34201.USD","LU2237443549.SGD","LU2462157665.USD","BK4568","LU0058720904.USD","LU0109394709.USD","LU2456880835.USD","LU2237443622.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2634101862","title":"流行病诊疗板块多股扬升 雅培(ABT)涨1.60%、强生(JNJ)涨1.12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2634101862","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634101862?lang=zh_cn&edition=full","pubTime":"2026-05-12 22:05","pubTimestamp":1778594751,"startTime":"0","endTime":"0","summary":"金吾财讯 | 汉坦病毒疫情叠加药企药物研发/合作进展向好消息提振，美股流行病诊疗板块多股扬升，截至发稿，葛兰素史克  涨 1.93%，雅培  涨 1.60%，默沙东  涨 1.41%，阿斯利康  涨 1.18%，强生  涨 1.12%。达歌生物周二宣布与默沙东研发(中国)有限公司签署合作协议，共同推进抗肿瘤药物临床合作开发。","market":"sh","thumbnail":"https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250107/MzZmY2I0ODMyNDljNDZhYjk1YmMwYzA2ZTYzZmI3NWMyMTczNjIzMDYxMjY4Mg==.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"300341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2213496289.HKD","LU2471134952.CNY","LU2360032135.SGD","LU0820561818.USD","IE00BSNM7G36.USD","IE00B3PB1722.GBP","LU0868494708.USD","LU0345769128.USD","LU1066053197.SGD","LU0006306889.USD","LU0889566641.SGD","LU2237443895.HKD","LU2896262040.SGD","LU0234572021.USD","LU0170899867.USD","LU0965509283.SGD","LU2237443465.HKD","LU1989772840.SGD","LU2361044949.HKD","LU1551013342.USD","LU0466842654.USD","LU1674673691.USD","LU1934455277.USD","LU2237443622.USD","IE00B2B36J28.USD","LU1057294990.SGD","IE00BGHQF631.EUR","LU0070302665.USD","LU2357627491.SGD","GSKH","BK4585","LU1721429402.USD","LU2089984988.USD","SG9999001176.SGD","LU1496350502.SGD","LU0545562505.USD","LU1023059063.AUD","LU2237443549.SGD","LU1778281490.HKD","LU0861579265.USD","BK4592","BK4581","LU1829250122.USD","SG9999002232.USD","LU1043141396.HKD","IE00BVYPNV92.GBP","LU2237443382.USD","LU0648001328.SGD","LU2237957902.USD","LU1032466523.USD","IE0002141913.USD","LU2505996681.GBP","LU1894683264.USD","LU0114720955.EUR","LU1201861249.SGD","LU2592432038.USD","LU0345769631.USD","LU2324357040.USD","SGXZ23171101.USD","LU2417539215.USD","LU2471134523.USD","LU0889565916.HKD","IE000F7OJYX1.SGD","LU1551013425.SGD","LU2361044865.SGD","LU2129689514.USD","IE00BFXG1179.USD","SGXZ57979304.SGD","BK4516","IE000BZT7R73.USD","LU0208291251.USD","LU0109394709.USD","LU0211331839.USD","LU1989763427.SGD","LU2756315318.SGD","LU1244550221.USD","LU2237443978.SGD","SG9999014575.USD","LU0265550946.USD","LU1929549753.HKD","LU0320765489.SGD","LU1674673428.USD","LU1074936037.SGD","LU0234570918.USD","LU0124676726.USD","ABT","IE000MB6IJN5.SGD","LU1066051225.USD","LU1430594728.SGD","LU2125154778.USD","LU2602419157.SGD","LU1032955483.USD","LU0477156953.USD","IE0002270589.USD","LU0106261372.USD","LU0640476718.USD","AZN","LU1989771016.USD","LU1121112475.USD","LU0345770308.USD","LU1162221912.USD","LU2430703178.SGD","LU2756315664.SGD","GSK.UK","IE00BKVL7J92.USD","LU0266013472.USD","LU1228905540.USD","IE0000B7K699.USD","BK4534","SG9999001440.SGD","LU1732800096.USD","LU0130102774.USD","BK4550","IE00B19Z3B42.SGD","LU2125154935.USD","LU1116320737.USD","LU0942090050.USD","LU1291159041.SGD","BK4007","LU0320765646.SGD","LU2491050154.USD","LU1261432733.SGD","LU0432979614.USD","LU1914381329.SGD","JNJ","LU0289739699.SGD","LU0689626769.HKD","LU1145028129.USD","LU1935042991.SGD","LU1721429741.USD","LU1974910355.USD","LU1267930813.SGD","LU2023250504.SGD","LU2129689431.USD","BK4568","LU1228905037.USD","IE00B4R5TH58.HKD","IE0034235303.USD","LU1069347547.HKD","LU0098860793.USD","LU2361045086.USD","SG9999002224.SGD","LU2236285917.USD","LU2430703251.USD","LU1244550494.USD","LU2461242641.AUD","LU2462157665.USD","LU2347655156.SGD","SG9999015358.SGD","LU0965508806.USD","LU1035773651.USD","LU0345770993.USD","LU0787776722.HKD","LU1037948897.HKD","IE00BFTCPJ56.SGD","LU1116320901.HKD","LU1732799900.SGD","LU0792757196.USD","LU0868494617.USD","LU1941712348.USD","IE000M9KFDE8.USD","LU0943347566.SGD","BK4532","LU2023250330.USD","LU0426417589.USD","LU2471134879.HKD","GSK","IE00BN8TJ469.HKD","LU1093756325.SGD","LU2403377893.USD","MRK","LU0689472784.USD","LU1983299246.USD","LU0985320562.USD","LU0238689110.USD","LU1196500208.SGD","IE00BLSP4239.USD","LU1571399168.USD","SG9999015341.SGD","LU0320765992.SGD","LU1244550577.SGD","SGXZ41872573.SGD","LU2487616109.SGD","IE00BJT1NW94.SGD","LU0994945656.USD","SG9999001176.USD","IE000SO60NU8.SGD","SG9999013999.USD","IE00B7SZLL34.SGD","IE0001KFT4U8.USD","LU1061106388.HKD","LU2456880835.USD","LU2491049909.HKD","LU1917777945.USD","IE00BZ1G4Q59.USD","LU2129689605.HKD","SG9999014559.SGD","LU1221951046.USD","LU0122379950.USD","LU0820562030.AUD","LU0053666078.USD","IE0009355771.USD","LU0980610538.SGD","LU0683600562.USD","LU0058720904.USD","LU1093756168.USD","LU1221951129.SGD","LU1585245621.USD","SG9999014542.SGD","LU0795875169.SGD","LU1989763690.USD","LU1718418525.SGD","IE000WAW04H5.SGD","IE00BLSP4452.SGD","LU1066051811.HKD","BK4533","LU1059921491.USD","LU1043141123.HKD","LU2106854487.HKD","IE00B19Z3581.USD","IE00B3T34201.USD","AZNH","LU0965509101.SGD","LU0265550359.USD","LU2023250843.SGD","LU2750360997.AUD","LU2471134796.USD","LU0210536198.USD","LU0203347892.USD","BK4082","LU2237957811.SGD","LU1934455863.HKD","LU0795875086.SGD","LU0130517989.USD","BK4588","LU1037948541.HKD","BK4559","LU1934455194.USD","LU1629891620.HKD","LU1989772923.USD","IE00BBT3K403.USD","IE00BVYPNW00.USD","LU0426412945.USD","LU0882574055.USD","LU2430703095.HKD","IE00B1BXHZ80.USD","IE00BJJMRZ35.SGD","LU1280957306.USD","LU1941712264.USD","IE00B42XCP33.USD","SG9999004303.SGD","LU1691799644.USD","LU1894683348.USD","LU1699723380.USD","LU2112291526.USD","LU0070217475.USD","LU0203345920.USD","SG9999014567.USD","LU2133065610.SGD","LU2750360641.GBP","BK4504","LU2491050071.SGD","LU0859254822.USD","LU1066051498.USD","IE00BDGV0183.EUR","LU0210528500.USD","LU0965509010.AUD","LU0912757837.SGD","LU0964807845.USD","LU0820561909.HKD","LU2211815571.USD","LU2468319806.SGD","LU2505996509.AUD","BK4566","LU1506573853.SGD"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2634544008","title":"世界狼疮日｜“主场时刻”患者关爱行动在沪启幕，助百万\"蝶友\"迈向临床缓解新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2634544008","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2634544008?lang=zh_cn&edition=full","pubTime":"2026-05-10 20:09","pubTimestamp":1778414940,"startTime":"0","endTime":"0","summary":"在2026年5月10日世界狼疮日，由新华网和患者组织SLE解忧杂货铺联合主办、阿斯利康中国支持的“主场时刻”系统性红斑狼疮患者关爱行动在上海正式启幕。全球范围内系统性红斑狼疮患者人数超过340万。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4955695_ZH55695_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU0109394709.USD","LU2237443622.USD","LU2237443382.USD","LU2237443465.HKD","LU1829250122.USD","LU2456880835.USD","AZNH","BK4110","LU2462157665.USD","SLE","LU2237443978.SGD","BK4568","BK4588","IE00B3T34201.USD","BK4077","BK4007","LU2417539215.USD","LU2237443549.SGD","LU0320765992.SGD","ACR","BK4585","LU2237443895.HKD","LU0289739699.SGD","LU0058720904.USD","LU0889565916.HKD","AZN","LU2236285917.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633794147","title":"多家药企高管生变：恒瑞、复星、阿斯利康、辉瑞…","url":"https://stock-news.laohu8.com/highlight/detail?id=2633794147","media":"赛柏蓝","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633794147?lang=zh_cn&edition=full","pubTime":"2026-05-07 19:53","pubTimestamp":1778154780,"startTime":"0","endTime":"0","summary":"01本土制药企业与Biotech迎高管变动恒瑞医药、再鼎医药、百济神州、和铂医药、复星医药映射出了中国创新药发展过程中企业所处的不同阶段。4月16日，恒瑞医药发布公告，正式完成新一届董事会和管理层聘任。复星医药4月2日，复星医药发布首席财务官变更公告，因工作安排调整，陈战宇辞去首席财务官职务。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-05-07/doc-inhxatff4708181.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU2237443382.USD","LU0306806265.USD","LU2237443895.HKD","BK4588","IE0002270589.USD","SG9999002224.SGD","06160","AZNH","IE00BBT3K403.USD","SG9999002232.USD","IE00B3T34201.USD","SG9999013999.USD","BK4568","BK4534","LU0170899867.USD","BK4533","LU0122379950.USD","SG9999001176.USD","LU2237443465.HKD","ONC","LU0320765992.SGD","BK4007","LU2417539215.USD","LU0109394709.USD","BK4550","LU0868494617.USD","LU2462157665.USD","LU0321505868.SGD","LU1057294990.SGD","LU1883839398.USD","SG9999011175.SGD","688235","BK4585","IE00B19Z3581.USD","PFE","LU2456880835.USD","BK4581","LU0289739699.SGD","LU0225284248.USD","BK4592","01276","IE00B19Z3B42.SGD","LU0321505439.SGD","LU0985481810.HKD","LU1066051498.USD","LU2237443622.USD","LU2237443549.SGD","SG9999003800.SGD","600196","LU0889565916.HKD","AZN","LU1066053197.SGD","LU1829250122.USD","SG9999001176.SGD","LU2237443978.SGD","LU1023059063.AUD","LU1894683348.USD","IE00BLSP4452.SGD","LU0234572021.USD","LU0306807586.USD","LU0456855351.SGD","BK4599","IE00BLSP4239.USD","02142","LU0058720904.USD","IE000M9KFDE8.USD","02196","LU2236285917.USD","SGXZ57979304.SGD","LU1894683264.USD","LU0225771236.USD","600276"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2633119830","title":"跨国药企业绩大爆发，集体加仓中国","url":"https://stock-news.laohu8.com/highlight/detail?id=2633119830","media":"21世纪经济报道","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2633119830?lang=zh_cn&edition=full","pubTime":"2026-05-07 16:19","pubTimestamp":1778141940,"startTime":"0","endTime":"0","summary":"炒股就看金麒麟分析师研报，权威，专业，及时，全面，助您挖掘潜力主题机会！　　2026年第一季度，全球制药巨头的业绩版图再度刷新。　　有券商医药行业分析师对21世纪经济报道记者表示，当前跨国药企的业绩已高度“超级重磅药化”，手握“王牌”产品足以决定公司的增长、估值乃至战略走向。默沙东与其他跨国药企一道，已将“加注中国创新”视为战略性防御与进攻并存的长期解法。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-05-07/doc-inhxahrf8322593.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU1201861249.SGD","LU1989772923.USD","LU1941712348.USD","LU2125154935.USD","LU0234572021.USD","LU2361045086.USD","LU1066051225.USD","LU0154236417.USD","SG9999015358.SGD","IE00BFTCPJ56.SGD","IE00B4R5TH58.HKD","IE00BJJMRZ35.SGD","SG9999013999.USD","AZN","LU2491050154.USD","IE00BSNM7G36.USD","LU0432979614.USD","LU2125154778.USD","BK4534","LU1917777945.USD","LLY","LU1941712264.USD","LU1069347547.HKD","LU0868494617.USD","IE00BJT1NW94.SGD","LU1037948897.HKD","LU1430594728.SGD","LU1057294990.SGD","LU0098860793.USD","IE000M9KFDE8.USD","LU0477156953.USD","LU2357627491.SGD","LU1162221912.USD","LU1934455194.USD","NVS","LU0965509101.SGD","LU0265550946.USD","LU1989771016.USD","LU2106854487.HKD","BK4559","LU2461242641.AUD","LU2089984988.USD","LU0130102774.USD","LU1934455277.USD","LU2360032135.SGD","NVOH","LU0985320562.USD","LU2468319806.SGD","LU0648001328.SGD","LU2491049909.HKD","LU0203345920.USD","BK4599","LU0289739699.SGD","LU0320765489.SGD","LU2023250843.SGD","MRK","SG9999001440.SGD","SG9999002232.USD","BK4007","LU1061106388.HKD","SG9999014575.USD","LU2324357040.USD","LU0265550359.USD","LU1116320901.HKD","LU1929549753.HKD","LU1934455863.HKD","LU0058720904.USD","LU0070302665.USD","LU2112291526.USD","IE00BZ1G4Q59.USD","BK4516","EUO","LU1116320737.USD","LU1066053197.SGD","IE00BBT3K403.USD","BK4588","SNY","LU0859254822.USD","LU0006306889.USD","LU0122379950.USD","LU0203347892.USD","LU1699723380.USD","MEURmain","LU0320765646.SGD","LU0868494708.USD","LU1093756168.USD","SG9999002224.SGD","LU2023250504.SGD","LU0861579265.USD","LU1037948541.HKD","IE00BKVL7J92.USD","IE00BLSP4452.SGD","IE00BN8TJ469.HKD","SG9999014567.USD","SG9999014542.SGD","LU1035773651.USD","IE00B1BXHZ80.USD","LU1989772840.SGD","LU0965509283.SGD","BMY","LU0211331839.USD","SG9999001176.USD","IE0009355771.USD","BK4533","LU0965508806.USD","LU2361044949.HKD","LU0965509010.AUD","IE00BLSP4239.USD","LU0238689110.USD","NVO","EURmain","LU0208291251.USD","LU1571399168.USD","LU0130517989.USD","LU1023059063.AUD","LU1291159041.SGD","LU0980610538.SGD","LU2491050071.SGD","LU0942090050.USD","BK4550","SG9999001176.SGD","LU0266013472.USD","LU0106261372.USD","FXE","SGXZ57979304.SGD","NVOX","BK4585","LU1974910355.USD","LU1093756325.SGD","LU2361044865.SGD","IE00B2B36J28.USD","BK4532","LU1983299246.USD","IE0002141913.USD","SG9999014559.SGD","LU1585245621.USD","SG9999015341.SGD","LU1066051498.USD","LU1066051811.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632260556","title":"诚益生物冲刺港股：年亏损4460万美元 业务深度绑定阿斯利康","url":"https://stock-news.laohu8.com/highlight/detail?id=2632260556","media":"雷递网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632260556?lang=zh_cn&edition=full","pubTime":"2026-05-03 10:35","pubTimestamp":1777775725,"startTime":"0","endTime":"0","summary":"诚益生物开曼有限公司（简称：“诚益生物”）日前更新招股书，准备在港交所上市。","market":"sh","thumbnail":"https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260503/6391340131178578595887971.jpeg","type":0,"news_type":0,"thumbnails":["https://leidinews-1256465536.cos.ap-chengdu.myqcloud.com/u_News/20260503/6391340131178578595887971.jpeg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.leinews.com/n33522/detail.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"leinews_highlight","symbols":["LU1829250122.USD","LU2237443465.HKD","LU2417539215.USD","LU0109394709.USD","LU2236285917.USD","VXUS","IE00B3T34201.USD","LU0889565916.HKD","BK4588","LU2462157665.USD","BK4568","BK4007","LU2456880835.USD","LU2237443549.SGD","LU0320765992.SGD","LU2237443382.USD","AZN","LU2237443895.HKD","LU2237443978.SGD","LU0289739699.SGD","BK4585","LU2237443622.USD","LU0058720904.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632619163","title":"伯恩斯坦将阿斯利康目标价从20500便士下调至18600便士。","url":"https://stock-news.laohu8.com/highlight/detail?id=2632619163","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632619163?lang=zh_cn&edition=full","pubTime":"2026-05-01 19:09","pubTimestamp":1777633776,"startTime":"0","endTime":"0","summary":"","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["AZNH","AZN","AZN.UK"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632504618","title":"阿斯利康乳腺癌候选药物未获FDA咨询委员会投票通过","url":"https://stock-news.laohu8.com/highlight/detail?id=2632504618","media":"环球市场播报","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2632504618?lang=zh_cn&edition=full","pubTime":"2026-05-01 16:14","pubTimestamp":1777623240,"startTime":"0","endTime":"0","summary":"在乳腺癌候选药物未能在一项关键的咨询委员会投票中获得支持后，英国制药集团阿斯利康表示，该公司将继续与美国监管机构合作，对该药物进行审查。该公司周四晚间表示，美国食品药品管理局的肿瘤药物咨询委员会以6比3的投票结果，对乳腺癌治疗候选药物camizestrant的获益-风险评估给出否定性意见。阿斯利康的股价在周五开盘交易中下跌了约1.8%。","market":"other","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/usstock/c/2026-05-01/doc-inhwktza5459710.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4568","AZN.UK","LU0320765992.SGD","LU2236285917.USD","LU2237443549.SGD","LU2237443465.HKD","LU2456880835.USD","LU2237443895.HKD","LU0109394709.USD","LU2237443978.SGD","LU2462157665.USD","LU2237443622.USD","LU0889565916.HKD","LU2237443382.USD","LU2417539215.USD","IE00B3T34201.USD","AZN","LU0289739699.SGD","AZNH","BK4585","BK4588","LU0058720904.USD","LU1829250122.USD","BK4007"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://www.astrazeneca.com","stockEarnings":[{"period":"1week","weight":-0.0236},{"period":"1month","weight":-0.0237},{"period":"3month","weight":-0.0733},{"period":"6month","weight":-0.0136},{"period":"1year","weight":0.191},{"period":"ytd","weight":-0.0358}],"compareEarnings":[{"period":"1week","weight":0.0211},{"period":"1month","weight":0.0212},{"period":"3month","weight":0.1253},{"period":"6month","weight":0.1243},{"period":"1year","weight":0.2644},{"period":"ytd","weight":0.1069}],"compareStock":{"symbol":"SPY","name":"标普500ETF"},"description":"阿斯利康股份有限公司于1992年6月17日根据1985年《公司法》在英格兰和威尔士注册成立。该公司是在1993年将Imperial化学工业公司的制药、农化和特种化学品业务分拆时成立的。1999年，公司出售了特种化学品业务。同样在1999年，该公司与瑞典Astra公司合并。2000年，该公司将农化业务分拆，并将其与诺华公司的同类业务合并，成立了一家新的公司Syngenta AG。2007年，集团收购了位于美国的生物制剂和疫苗企业MedImmune。2021年，集团收购了位于美国的罕见病企业Alexion。","yearOnYearQuotes":[{"month":1,"riseRate":0.515152,"avgChangeRate":0.001662},{"month":2,"riseRate":0.424242,"avgChangeRate":-0.012868},{"month":3,"riseRate":0.545455,"avgChangeRate":0.025511},{"month":4,"riseRate":0.636364,"avgChangeRate":0.028791},{"month":5,"riseRate":0.515152,"avgChangeRate":0.008212},{"month":6,"riseRate":0.441176,"avgChangeRate":0.016465},{"month":7,"riseRate":0.606061,"avgChangeRate":-0.002513},{"month":8,"riseRate":0.484848,"avgChangeRate":0.004788},{"month":9,"riseRate":0.545455,"avgChangeRate":0.001232},{"month":10,"riseRate":0.545455,"avgChangeRate":0.015301},{"month":11,"riseRate":0.515152,"avgChangeRate":0.003764},{"month":12,"riseRate":0.545455,"avgChangeRate":0.007464}],"exchange":"NYSE","name":"阿斯利康","nameEN":"AstraZeneca PLC"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"阿斯利康,AZN,阿斯利康股票,阿斯利康股票老虎,阿斯利康股票老虎国际,阿斯利康行情,阿斯利康股票行情,阿斯利康股价,阿斯利康股市,阿斯利康股票价格,阿斯利康股票交易,阿斯利康股票购买,阿斯利康股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"阿斯利康(AZN)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供阿斯利康(AZN)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}